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Role of Proto-oncogene Activation in
Carcinogenesis
by Marshall W. Anderson,1 Steven H. Reynolds,1 Ming
You,1 and Robert M. Maronpot1
The accumulation of genetic damage in the forms of activated proto-oncogenes and inactivated tumor-
suppressorgenesisthedrivingforceintheevolutionofanormalcelltoamalignantcell.Forexample,boththe
activation ofras oncogenes andtheinactivation ofseveral suppressorgenes,includingp53,havebeenobserved
in the development ofhuman colon and lung tumors. Point mutations in key codons can activate ras proto-
oncogenes and inactivate thep53 suppressorgene.Thus, several critical genes fortumorigenesis arepotential
targets for carcinogens and radiation that can induce point mutations at low doses. Theras proto-oncogenes
are targets for many genotoxic carcinogens. Activation of the ras gene is an early event-probably the
"initiating"step-inthedevelopmentofmanychemical-inducedrodenttumors.rasOncogenesareobservedin
more humantumors andatahigherfrequencythan anyotheroncogene,andactivation oftheproto-oncogene
may occur atvarious stages ofthe carcinogenic process. Numerous proto-oncogenes otherthantheras genes
have been shown to be activated in human tumors and to a lesser extent in rodent tumors. Mechanisms that
induceaberrantexpressionofproto-oncogenes aregeneamplificationandchromosomaltranslocationorgene
rearrangement.Amplificationofproto-oncogenesandpossiblygeneoverexpressionduringtheabsenceofgene
amplificationoccurinthedevelopmentofmanyhumantumors.Foraspecifictumortype,amplificationofany
one proto-oncogene may occur at a low frequency, but the frequency oftumors in which at least one proto-
oncogene isamplifiedcanbemuchhigher.Proto-oncogeneamplificationisusuallyassociatedwithlatestages
oftumor progression; however, amplified HER2/neu has been observed in early clinical stages ofmammary
neoplasia.Activation ofproto-oncogenes bychromosomaltranslocation hasbeendetected atahighfrequency
in several hematopoietic tumors. Non-ras geneshavebeendetectedbyDNAtransfection assaysinbothhuman
androdenttumors.Forexample,retandtrkgeneswerefoundtobeactivatedbygenerearrangements inhuman
papillary thyroid carcinomas. Several potentially new types of oncogenes have also been detected by DNA
transfection assays. The etiology of the genetic alterations observed in most human tumors is unclear at
present.Examplesofrasgeneactivation andthosedocumentedformutationsinthep53genedemonstratethat
exogenousconditions caninduceoncogenicmutants ofnormalgenes.Thegeneticalterationsobservedinmost
human tumors are probably generated by both spontaneous events and exogenous conditions.
Introduction
Anincreasing amount ofevidence suggests that a small
set of cellular genes appears to be the target for genetic
alterations that contribute to the neoplastic transforma-
tion of cells. The development of neoplasia may, in many
cases, require changes in at least two classes of cellular
gene: proto-oncogenes (1-12) andtumor-suppressor genes
(13-16). Forexample, activation ofthe K-ras oncogene and
inactivation ofatleastthree tumor suppressor genes have
been observed in the development ofhuman colon tumors
(17). This report will discuss the activation of proto-
oncogenes in human and rodent tumors and the role of
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these oncogenes in the etiology and development of
tumors.
Proto-oncogenes
Proto-oncogenes are expressed during "regulated
growth," such as embryogenesis, wound healing, regen-
eration ofdamagedliver, and stimulation ofcellmitosisby
growth factors. Proto-oncogenes are highly conserved,
being detected in species as divergent as yeast, Dro-
sophila, and humans. These genes encode for growth fac-
tors,growthfactorreceptorswithtyrosinekinaseactivity,
regulatory proteins in signal transduction, nonreceptor
tyrosinekinases, serine/threonine kinases, andtranscrip-
tion factors (Table 1). The encoded proteins play a crucial
role in cellular growth and differentiation (1,5-8) and in
apoptosis or programmed cell death (18).
Proto-oncogenes were initially identified as the trans-
duced oncogenes of acute transforming retroviruses (9).ANDERSON ETAL.
Table 1. Biological functions ofcellular proto-oncogenes.
Function Proto-oncogenes
Growth factor sis (PDGF), int-2, hst-1
Growth factor receptor with erb B (EGF receptor),fms (CSF
tyrosine kinase activity receptor), met (HGF receptor),
neu, ros, trk, ret
¶1yrosine kinase src, ab4 lck, yes
Regulatory protein in signal Ha-ras, K-ras, N-ras, gsp, gip
transduction
Serine/threonine kinase moe, raf
Nuclear regulatory protein myc, myb, fox, c-jun, rel
Viral oncogenes arise by recombination between cellular
proto-oncogenes and the genome of nontransforming
retroviruses. Proto-oncogenes can also be activated to
cancer-causing oncogenes by mechanisms independent of
retroviral involvement (1,3,10-12). These mechanisms
include point mutations and gross DNA rearrangements
such as translocation and gene amplification, and it is
these mechanisms that generate the oncogenes observed
in human and rodent tumors.
The rasfamilyofproto-oncogenes isofparticularinter-
est since these genes have been implicated in the develop-
ment of numerous tumors. H-ras, K-ras, and N-ras can
acquire transforming activityby apoint mutation in their
coding sequence. In vivo, activating point mutations have
been observed in codons 12,13, 61, 117, and 146 (19-21). We
haverecentlydetected a30-baserepeataroundcodon61in
the K-ras gene in several mouse tumors; this repeat
appears to activate the K-ras gene.
The ras gene products are 21,000-Da proteins (p21)
which bind guanine nucleotides with high affinity and are
thought to be involved in various signal transduction
pathways in many cell types (22-24). The p21:GDP com-
plex receives a signal from an upstream element (i.e., an
activated membrane-bound receptor), and the GDP is
exchanged for GTP to convert the inactive p21:GDP com-
plex to the active p21:GTP complex (25). The p21:GTP can
transmit the signal downstream to an appropriate target.
The active GTP complex with p21 is converted to the
inactive GDP complex by hydrolysis ofGTP to GDP. The
p21 protein itself possesses intrinsic GTPase activity;
however, in Vivo, this intrinsic activityis very slowunless
enhanced by GTPase-activating protein (GAP). GAP can
enhance the GTPase activity ofp21 by at least a factor of
4 x 103.Thefirstobserveddifferenceinbiological activity
between amutantoncogenicp21andwild-typep21 wasthe
intrinsic GTPase activity, which was 10 times higher in
wild-type than in the valine-12 oncogenic mutant. It soon
became clear, however, that intrinsic GTPase activity
could not be used to differentiate between some mutant
forms ofp21 observed in human tumors and thewild-type
ras protein (26). After the discovery ofGAP, it was shown
that the main biochemical difference between oncogenic
p2lswithmutations incodon12,13, or61andwild-typep21
isthe abilityofGAPtoinduceGTPhydrolysisintheactive
p21:GTP complex. The GAP-induced hydrolysis can be as
much as 1000 times greater in the wild-type p21 than in
these mutant forms ofras (27,28). The mutant forms thus
remain in the active GTP form much longer than the wild
type, and presumably the continual transmission of a
signal bythe mutantforms is responsible, atleastinpart,
for the oncogenic properties. The mutations in codon 117
and 146 increase the GDP:GTP exchange rate and thus
increase the amount of cellular p21:GTP complex in the
absence ofanexternalsignal, sincethecellularconcentra-
tion ofGTP is much greater than that ofGDP. The codon
117 and 146 mutations have been observed only in rodent
tumors. The crystal structure of p21 and some of the
mutant oncogenic p2is have recently been determined by
two groups (29-32). Although some structural differences
areobservedbetweentheoncogenicandwild-typep21,the
X-ray crystal structural differences between wild-type
p21 and oncogenic mutants do not clearly explain the
dramatic differences in response to GAP (30,31).
rasOncogenes in Human and Rodent
Tumors
A ras oncogene was the first activated proto-oncogene
detected in a human tumor, and the K-, H-, and N-ras
oncogenes havebeendetectedinmorehumantumortypes
and atahigherfrequencythan anyother oncogene (Table
2). Activated ras proto-oncogenes have been detected in a
relativelyhighpercentage ofcoloncarcinomas (47%),pan-
creatic carcinomas (81%), lung adenocarcinomas (32%),
cholangiocarcinomas (88%), certain types of thyroid
tumors (56%), endometrical adenocarcinomas (47%), mu-
cinousadenocarcinomas oftheovary(75%),squamous-cell
carcinomas (SCC) at sun-exposed body sites (47%), oral
SCC associatedwithtobacco/quidchewing(35%), and to a
lesser extent in several other types of human tumor. In
some tumortypes, however, detection ofaras oncogeneis
a rare event; these include mammary adenocarcinomas
(1/55), hepatocellular carcinomas (2/57), cervical carcin-
omas (1/24), and oral SCC from patientswho do not chew
tobacco (1/32).
Activated ras proto-oncogenes have also been detected
in spontaneous and chemical-inducedtumors generated in
numerous rodent model systems (Table 3) (3,19,73-79).
The reproducible activation ofras oncogenes in chemical-
induced rodent tumors has made it possible to correlate
the activating mutations with the promutagenic adducts
formed either directly or by metabolic activation of the
carcinogen. For example, mutational spectra have been
determined in ras oncogenes detected in tumors gener-
atedinmouselymphocytes (78),mouseliver(20,96),mouse
and ratskin (76,93), mouse andratlung(81,82,89), and rat
mammary gland (84,85). In most of these cases, the
observed mutational spectrum in the ras oncogenes is
consistentwiththepatternofDNAadductsinducedbythe
genotoxic carcinogen and is also consistent with in-vitro
mutation patterns, such as those generated in the lacI
gene of Escherichia coli by methylating agents and
benzo[a]pyrene (81). Onestrikingexampleisthatinwhich
there is selectivity for the ras mutation spectrum but no
correlation with the known DNA adducts. Activation of
H-rasandK-rasoncogenesinthe secondbaseofcodon61,
A:Tto T:AorG:C, byethyl carbamate orvinyl carbamate
(the putative proximal carcinogenic metabolite of ethyl
carbamate) has been observed in mouse skin (97), mouse
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Table 2. ras Oncogenes detected in human tumors.a
No. positive/
Tumor no. tested Oncogeneb References
Colon
Adenomas (FAP) 10/115 K-ras (10) (33,34)
Adenomas 36/84 K-ras (35), N-ras (1) (34-36)
Carcinomas 136/289 K-ras (131), N-ras (5) (34-38)
Metastases 35/61 K-ras (32), N-ras (3) (35,39)
Ulcerative colitisc 1/17 K-ras (1) (38)
Pancreatic carcinomas 174/220 K-ras (174) (35,38,40-43)
Lung adenocarcinomas 65/207 K-ras (59), H-ras (2), (44-47)
N-ras (4)
LungSCC 4/60 H-ras (3), N-ras (1) (44,48)
Thyroid
Adenomasd 20/29 H-ras (14), N-ras (5), K-ras (1) (49,50)
Follicular carcinomasd 11/21 H-ras (7), N-ras (3), K-ras (1) (49,50)
Undifferentiated carcinomase 6/10 H-ras (3), N-ras (1), K-ras (2)
Adenomase 2/12 H-ras (1), N-ras (1) (49)
Follicular carcinomase 1/10 H-ras (1) (49)
Papillary carcinomasf 2/51 N-ras (2) (49,51,52)
AML 12/45 K-ras -(10), N-ras (2) (53)
Pre-AML cells, MDS 3/8 N-ras (3) (54)
Pre-AML cells, MDS 2/4 K-ras (2) (55)
CML, chronic phase 1/6 H-ras (1) (56)
CML, blast phase 3/6 H-ras (2), N-ras (1) (56)
SCCg 15/32 H-ras (15), K-ras (1) (57,58)
Basal-cell carcinomas' 5/16 H-ras (5) (58)
Keratoacanthomas 16/50 H-ras (16) (59)
Cutaneous melanomash 7/37 N-ras (7) (60)
Oral SCC' 20/57 H-ras (20) (61)
Oral SCCI 1/32 H-ras (1) (62,63)
Hepatocellular carcinomas 2/57 K-ras (1), N-ras (1) (64-66)
Cholangiocarcinomas 21/24 K-ras (21) (66,67)
Bladder carcinomas 7/62 H-ras (7) (68,69)
Endometrial adenocarcinomas 15/42 K-ras (14), N-ras (1) (70,71)
Cervical carcinomas 1/28 K-ras (70,71)
Ovary
Mucinous adenocarcinomas 9/12 K-ras (9) (70,71)
Differentiated nonmucinous 3/28 K-ras (3) (70,71)
Invasive mammary adenocarcinomas 1/55 K-ras (1) (72, unpub-
lished obser-
vations)
Abbreviations: FAP,familialpolyposis colipatients; SCC, squamous-cell carcinoma; AML, acutemyeloidleukemia; MDS,myelodysplastic syndrome;
CML, chronic myeloid leukemia.
'The basis for detection ofthe oncogenes listed in this table is the DNA transfection assay and biochemical assays such as the polymerase chain
reaction and the RNAse-A-mismatch-cleavage method.
bNumbers in parentheses indicate the number ofsamples with that oncogene.
cCarcinomas and dysplasia arising in patients with ulcerative colitis.
dFrom iodide-deficient areas.
eFrom areas ofnormal dietary iodide intake.
fFrom both iodide-deficient and normal iodide intake areas.
'Sun-exposed body sites. hlTmors positive for ras activation were localized on body sites continuously exposed to sunlight.
'From Indian patients who chewed tobacco/quid.
JFrom patients in the United Kingdom who did not chew tobacco, although some were smokers.
liver (96), and mouse lung (81) tumors; however, the only
reported adduct to date is a deoxyguanosine adduct (98-
100). Detailed discussions ofthe relationship between ras
mutational spectra observed in chemical-induced tumors,
and the known DNA binding properties of the chemical
are presented in some ofthe above-mentioned references
(20,76,78,81,84,85,93,96).
Many chemicals that induce tumors in rodents have no
detectable DNA damaging activity in genotoxicity assays
in vitro (101). Classical "nongenotoxic" tumor promoters
such as 12-O-tetradecanoylphorbol-13-acetate, phenobar-
bital, and2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) can
confer a selective growth advantage to cells initiated by
genotoxic agents; however, nongenotoxic chemicals, in-
cluding some ofthe classical tumor promoters, can induce
tumors in rodent model systems without the help of exo-
genous genotoxic chemicals. The mouse liver is amodel in
which manynongenotoxic chemicalsinducehepatocellular
neoplasia (101): chemicals that have this property include
TCDD, phenobarbital, polychlorinated biphenyls, furan,
tetrachloroethylene, trichloroethylene, the class ofchemi-
calsdesignated asperoxisomeproliferators (whichinclude
manytherapeutic agents and industrial agents), and chlo-
rinated insecticides such as chlordane. Since spontane-
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Table 3. ras Oncogenes and activating mutations detected in rodent tumors.
Oncogene Activation
Condition Rodenta Tumor (frequency) mutationsb References
Spontaneous B6C3F1 Lung K-ras (3/16) G35-+ A (80, unpub-
lished obser-
vations
Spontaneous A! J Lung K-ras (19/20) G35 -+ TAA'82-+ G (81,82)
Spontaneous B6C3F1 Liver H-ras (67/103) C181 -+A;A182 G,T (20,83,
unpublished
observations)
Spontaneous C57 Liver H-ras (2/12) A182-+ T (unpublished
observations)
MNU Ratc Mammary H-ras (61/70) G35-+ A (84,85)
MNU Wistar rat Thyroid H-ras (14/15) ND (86)
Ionizing radiation Wistar rat Thyroid K-ras (9/15) ND (86)
DMN-OME Fischer rat Kidney K-ras (10/35) G35-+ A (87)
MBNA Fischer rat Esophagus H-ras (18/18) G35-+ A (88)
Tetranitromethane B6C3F1 Lung K-ras (10/10) G35-+ A (89)
Tetranitromethane Fischer rat Lung K-ras (18/19) G35 -+ A (89)
1,3-Butadiene B6C3F1 Lung K-ras (6/9) G37 -+ C (90)
BP A/J Lung K-ras (14/16) G34-+ T G35 -+ A (81)
BP NIH/Swiss Skin H-ras (2/5) G35+ T (73)
DMBA NIH/Swiss Skin H-ras (58/61) A182 -* T (76)
DMBA Rat C Mammary H-ras (6/29) A182-+ N (85)
DMBA Rabbit Skin H-ras (5/10) A'62-+ T (91)
DMBA Rabbit Skind H-ras (10/17) A'62-* T (59,91)
BOP Hamster Pancreas K-ras (10/10) G35-+ A (92)
Benzidine congeners Fischer rat Skin and H-ras(31/50) G37 -+C;C18' -+ A (93) and dyes other N-ras (3/50)
Benzidine B6C3F1 Liver H-ras (13/22) C'8 -+ A (83)
Aflatoxin B, Fischer rat Liver K-ras (3/13) G 3 T;G35 -+ A (94,95)
N-ras (5/13)
Furan B6C3F1 Liver H-ras (10/29) C'6' -+A;G351 -* C,T (20)
K-ras (2/29)
Tetracholorethylene B6C3F1 Liver H-ras(11/40) C'6' -+ A;A'62-+ T (unpublished
K-ras (6/40) observations)
Phenobarbital B6C3F1 Liver H-ras(1/15) C181 -+ A (83)
Abbreviations: MNU, N-methyl-N-nitrosourea; DMN-OME methyl(methoxymethyl)nitrosamine; MBNA, methylbenzylnitrosamine; BP,
benzo[a]pyrene; DMBA, 7,12-dimethylbenz[a]anthracene; BOP, N-nitrosobis(2-oxopropyl)amine; ND, not determined.
aMouse strains were used unless otherwise noted.
bOnly mutations that occur atrelatively high frequency.
CBuf/N, Sprague-Dawley, and Fischer 344 strains.
dKeratoacanthomas.
ouslyoccurringtumorsintheB6C3F1 mousestrainhave a
high incidence of activated H-ras genes, the pattern of
activated ras genes in spontaneous tumors and in those
induced by nongenotoxic chemicals has been compared in
several studies to help determine the mechanisms by
which nongenotoxic chemicals induce tumors (20,83). For
example, trichloroethylene appears to promote the "spon-
taneouslyinitiatedcells"thatdevelopintotumorsinuntre-
ated animals, whereas furan and tetrachloroethylene
induce ras mutational spectra distinct from those
observedinspontaneoustumors(20;unpublishedobserva-
tions). Incontrast,phenobarbital appearsto selectagainst
ras-initiated cells in that only 1 of 15 tumors induced by
this compound had H-ras oncogenes compared to 66% in
spontaneous tumors (83). Additional studies are required
to delineate the mechanisms by which these various non-
genotoxic chemicals induce mouse liver tumors as well as
tumors in other rodent model systems.
The spectrum of K-ras codon 12/13 mutations detected
in human lung, colon, and pancreatic tumors is shown in
Table 4. Even thoughthe datainTable 4represent diverse
population groups, lung and colon tumors show a distinct
difference intheirspectra. Inlungadenocarcinomas, the-G
to T mutation in the first base of codon 12 occurs at the
highest frequency (53%), whereas this mutation accounts
Table 4. SpectrumofK-ras codon12/13 mutations in humantumors.a
Colonb Lung Pancreas
Mutation (n = 166) (n = 75) (n = 168)
K12 (GGT)
TGT boc 53 11
GTT 20 15 28
GAT 38 15 39
AGT 7 1 1
CGT 1 4 18
GCT 2 7 1
K13 (GGC)
GAC 22 3 1
TGC 0 1 0
CGC 0 1 0
aColon tumors consist of adenomas and adenocarcinomas, and lung
and pancreatic tumors are adenocarcinomas. Data obtained from refer-
ences in Table 2 and M. Perucho (personal communication).
bData from Burmer et al. (38) are not included, since they observed
mainlyGGTtoAGTmutationsincodon 12(32of37totaltumorswith ras
mutations) and only4of37with GtoTmutations. Thus, theirmutational
spectrumisverydifferentfromthatobservedintheotherstudiesofcolon
tumors.
cNumbers are percentages oftotal number of K-ras 12113 mutations.
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foronly10% ofthemutations in colon tumors. In contrast,
G to A mutations in the second base of codon 12 or 13
account for 60% ofthe mutations in colon tumors and for
only 18% of the mutations in lung tumors. Pancreatic
tumorshave similarfrequencies ofGtoT(39%)andGtoA
(41%) mutations. The K-ras oncogene mutational spectra
observedinpancreatic carcinomas showconsiderablevari-
abilitybetween individual studies (38); the spectrainlung
and colon tumors are similar in thevarious investigations,
except forthat ofBurmer et al. (38), noted in Table 4. This
does notimplythatthe dataofBurmeretal. areincorrect
but that further analysis oftheir population group would
be ofinterest.
The difference in the K-ras mutational spectrum in
colon and lung is probably mainly a consequence of ciga-
rette smoking.Althoughtheassociation ofSCC andsmall-
cellcarcinomasofthelung(SCLC)withcigarettesmoking
is well established, only recently has a clear association
with adenocarcinomas been suggested (102). Philips et al.
(103) have shown alinearrelationshipbetween numbers of
cigarettes smoked and DNA adduct levels in the lung.
Thus, the activated ras genes detected in human pulmon-
aryadenocarcinomasfromsmokersprobablyresultfroma
direct genotoxic effect of carcinogens present in tobacco
smoke. Comparison of the frequency of detection of ras
genes in smokers and nonsmokers strongly supports this
hypothesis: An activated ras proto-oncogene was not
detected in six of six nonsmokers or in three of four
adenocarcinomas frompatientswho had stopped smoking
at least 5 years before diagnosis, whereas 44% (27/62) of
adenocarcinomas from smokers had activated ras genes
(data from references 44 and 45, in which the status of
smoking was given). The pattern of mutations in K-ras
oncogenes detected in lung tumors induced in mice by
benzo[a]pyrene is very similar to that observed in human
pulmonary adenocarcinomas (Tables 3 and 4). Colon
tumorigenesis in humans is not associated with cigarette
smoking. Cigarette smoking represents the most consis-
tently observed risk factor for induction of pancreatic
tumors, although the small relative risk associated with
cigarette smoke indicates that other conditions are impor-
tant. The G to T mutations observed inpancreatic tumors
could arise, in part, from cigarette smoking.
Several recent studies have examined the patterns of
the p53 gene mutations detected in human tumors
(104,105). G:C to T:A mutations are the most frequently
observed (57%) mutationsinthep53genefromnon-SCLC
(104), and this pattern is thus similar to that of K-ras
mutation in pulmonary adenocarcinomas (Table 4). Even
though the p53 mutations were detected mainly in SCC
and the K-ras mutations mainly in adenocarcinomas, it is
very noteworthy that the same mutational pattern is
observed in two cancer-causing genes detected in tumors
associated with cigarette smoking. Comparison of p53
mutations detected in colon tumors with the K-ras muta-
tions in this tumor type reveals not only a similarity but
also a distinct difference. G:C to A:T transitions are the
predominantmutationsinbothgenes.Thismutationinthe
p53 gene occurs at CpG dinucleotides and could result
from spontaneous deamination of the 5'-methylcytosine
residues (104); however, this type of mechanism cannot
account for the G:C to A:T transitions observed in the
K-ras oncogenes detected in colon tumors.
In addition to possible activation of the K-ras proto-
oncogene by chemicals in cigarette smoke, several other
examples arepresentedinTable2inwhichrasgeneswere
probably activated by exposure of humans to exogenous
agents: a) ras Oncogenes were detected in subcutaneous
SCC, basal-cell carcinomas, and melanomas from sun-
exposedareasofthebodybutatamuchlowerfrequencyin
tumors obtained from unexposed sites; moreover, the
mutations observed in H-ras oncogenes detected in SCC
and basal-cell carcinomas are consistent with ultraviolet
radiation-induced DNAlesions (58). b) Oral SCC obtained
from Indian patients who chewed tobacco/quid contained
activated H-ras genes, whereas oral SCC from patients
whodidnotchewtobaccohadaverylowincidenceofH-ras
oncogenes. c) A high incidence of ras oncogenes was
observed in thyroid follicular carcinomas and adenomas
frompeople livingin iodide-deficient areas, and theywere
detected at a much lower frequency in these types of
tumor obtained from people living in geographical areas
where iodide consumption was normal. ras Oncogenes
were detected at averylowfrequencyinthyroid papillary
carcinomas, without regard to the levels ofiodide intake.
Thus, iodide deficiency is related to high rates of ras
activation in thyroid follicular carcinomas and adenomas.
These examples of ras gene activation and those docu-
mented for mutations in the p53 gene (104) demonstrate
that exposure of humans to environmental agents or
abnormaldietaryconditionscaninduceoncogenicmutants
ofnormal genes.
Several conclusions about the role of ras genes in car-
cinogenesis can be inferred from the data and references
presented in Tables 2-4. First, activation of ras proto-
oncogenes is an early event in many rodent tumors. This
deduction is based on several observations: a) ras muta-
tions are chemical specific and are observed after a single
dose of carcinogens; b) ras oncogenes are detected in
adenomas,which cangiverise to carcinomas; c) ras muta-
tions havebeen detected inpreneoplastic lesions in mouse
lungand liver (unpublished data), and the same mutations
aredetectedinthecarcinomas;d) rasmutationshavebeen
detected very soon after exposure to a carcinogen-in rat
mammary tissue 2 weeks after neonatal exposure to
N-methyl-N-nitrosourea (106) and in mouse lung tissue
several days after exposure to this nitrosamine (unpub-
lished data). rasActivation is probablytheinitiating event
in the development of many chemical-induced tumors;
moreover, a cell with an activated ras gene can exist in a
tissue until endogenous or exogenous factors promote
clonal expansion ofthe initiated cell.
Second, activation oftherasgeneinhumantumorsmay
occur at various stages of the carcinogenic process. ras
Oncogenes were detected in colonadenomas, andin allbut
one sample the K-ras oncogene detected in the carcinoma
was also presentinthe surroundingadenoma(37,107). ras
Oncogenes have been detected in myelodysplastic syn-
drome and could be involved in progression to malignant
acute myelogenous leukemia (54,55). ras Oncogenes are
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probably a late event in the development of cholangiocar-
cinoma because they are detected in less than 10% ofthe
cells in the carcinoma (67). ras Oncogenes are detected in
colon metastases (Table 2), and arecent report suggested
that ras activation may be involved in the metastatic
process, asinsomecasesmutations detectedinthemetas-
tases were different from those observed in the primary
tumor (39).
Third, in addition to being observed in malignant
tumors and in adenomas, which can progress to a malig-
nant tumor, ras oncogenes have also been detected in
several benign tumors which either are self-regressing
and/or have a very small probability of progressing to
malignanttumors. These tumortypesincludehuman skin
keratoacanthomas and basal-cell carcinomas (Table 2).
Thus,rasactivationisnotsufficientinallcasestopromote
the continual growth ofa tumor, and subsequent accumu-
lationofadditionalgeneticdamageisrequiredtomakethe
tumor invasive and metastatic. These examples are not
inconsistent with the observation that ras oncogenes can
induce differentiation in neuronal (108,109), endocrine
(110), lymphoid (111), and fibroblast (112) cells.
Fourth, the frequency with which ras oncogenes are
detected in human tumors depends on the differentiation
andsubtype: forexample,a) K-rasoncogenesaredetected
incolonvillousadenomasandvilloglandularpolypsbutnot
in papillary adenomas; b) ras oncogenes are detected in
thyroid follicular andundifferentiated carcinomas but at a
much lower frequency in papillary carcinomas; c) K-ras
oncogenes are detected in ovarian mucinous adenocar-
cinomas but at a much lower frequency in differentiated
nonmucinous tumors; and, d) K-ras oncogenes detectedin
pulmonary adenocarcinomas may occur predominantly in
the subtypes ofthis tumor that are associated with ciga-
rette smoking (102).
Fifth, the correlation between humans and rodents of
the role of ras gene activation in tumor development is
variable (Tables 2 and3). Forhumanpulmonaryadenocar-
cinomasandpancreaticcarcinomas,thereareanimalmod-
els in which K-ras oncogenes are involved in the tumor
process. Human thyroid follicular and undifferentiated
tumors contain all three ras oncogenes, and rat thyroid
tumors have been induced which contain H- and K-ras
oncogenes. Rodent and human subcutaneous SCC and
basal-cell carcinomas contain activated H-ras oncogenes.
Human and rabbit skin keratinoacanthomas contain
H-ras oncogenes. In contrast, ras oncogenes are detected
at ahigh frequencyin several rodent tumor types but at a
very low frequency or not at all in the corresponding
human tumors: for example, a) H-ras in mouse hepato-
cellular tumors but not in the corresponding human
tumors; b) H-ras in rat mammary adenocarcinomas but
not in human mammary tumors; and c) K-ras in rat lung
SSC but not in human lung SSC.
Non-ras Oncogenes in Human and
Rodent Tumors
Numerous proto-oncogenes other than the ras genes
havebeen showntobe activated inhumantumors andto a
much lesserextent, inrodenttumors. Recently, the classi-
cal heterotrimeric G proteins were detected in an onco-
genicform in human endocrine tumors (113-115). These G
proteins areinvolvedin signaltransductionpathways. For
example, they can mediate the activation of adenylyl
cyclase andtheproduction ofc-AMPinresponsetotropic
hormones and can also promote the growth of some
endocrine cells. Point mutations in the chains ofGia were
observedin3 of11tumors ofthe adrenalcortexand3 of10
endocrine tumors ofthe ovary (15). The mutant a gene of
Giais designatedgip2, aputativeoncogene.The a. chainof
G. was observed to contain a point mutation in 18 of 42
growth hormone-secreting pituitary tumors (15). The
mutantachainofG.isdesignatedgsp.Thepointmutation
in the gene inhibits the GTPase activity ofthe a protein
and thus keeps the G protein in the active GTP complex.
Thus,themechanismofproto-oncogene activation ofthea
genes is similar to that observed for the ras genes.
Induction ofaberrantexpression ofproto-oncogenes by
geneamplification orchromosomal translocation hasbeen
observed in avariety oftumors (1,3-5,10-12). Proto-onco-
gene amplification is observed as both a low-frequency
eventin diverse tumortypes and as ahigh-frequency event
inspecifictumortypes.Thefollowingexamplesillustratethe
amplification ofproto-oncogenes in human tumors.
Neuroblastomas. N-myc amplification has been ob-
servedinmorethan50%ofthetumorsexamined(116-118).
Amplification of N-myc appears to be restricted to the
most aggressive tumor cells, and the degree ofamplifica-
tion is inversely related to survival time (116,118-121).
Clinically,amplificationofN-mycmaybeabetterprognos-
tic factor than the stage ofthe tumor (122).
Breast Adenocarcinomas. Several proto-oncogenes
havebeenobservedtobeamplifiedinthistumortype.The
frequenciesofincreasedcopynumberofc-mycrangefrom
a low 1-2% (123,124) to a much higher 14-48% (125,126).
Perhaps the most interesting observation has associated
c-myc amplification with hormone receptor negativity
(125), high tumor grade (125), and older patient age (126).
Coamplification ofint-2 andhst-1hasbeenfoundin9-23%
ofbreast cancers (127). In contrast, amplification ofint-2
andhst-1isobservedmostofteninsteroid-positivetumors
and may define a small subset of node-negative breast
cancer patients who are at high risk (127). The reported
amplification rates for HER2/neu range from 10 to 46%
(123,124,128-130). Table 1 in reference128 summarizes the
earlier findings for HER2/neu amplification. This proto-
oncogene is amplified in both node-negative and node-
positive breast cancers (123,128,129), even though it tends
to be more frequent in patients with larger numbers of
positive nodes. The value of HER2/neu as a prognostic
factor in node-negative patients is controversial
(123,128,129) and maybe limited to a small subset ofsuch
patients (123). Thus, amplification of various proto-
oncogenes appears to play an important role in the devel-
opmentofhumanbreastcancer,althoughtheamplification
of a specific oncogene may be limited to a small subset of
mammary tumors.
Gastric Adenocarcinomas. Several oncogenes have
been found to be amplified in tumors ofthis typebuteach
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at a relatively low frequency: C-myc (4%), hst-1 (6%),
HER2/neu (6%), and K-ras (10%) (131). Of 50 patients
analyzed, at least one of these genes was amplified, and
several patients hadmorethan oneofthe genes amplified.
Other studies have shown that HER2/neu is amplified in
10%ofgastriccarcinomas,especiallyinwell-differentiated
adenocarcinomas (132-135).
Lung Tumors. L-myc has been found to be amplified in
5-20% ofprimary SCLC (136-1q9) but very infrequently
in non-SCLC (136,140). N-myc was amplified in 0-10% of
primary SCLC (136) but very infrequently in non-SCLC
(136). N-myc and L-myc amplification and overexpression
are characteristic of SCLC. C-myc has been detected as
amplified in 0-20% ofSCLC (136-139) and 10-30% ofnon-
SCLC (136,139-141). Thus, amplification of genes of the
myc family may be involved in the development of some
humanlungtumors. Overexpression ofthesegenesoccurs
at a higher rate: N-myc overexpression was observed in
46% of SCLC samples in one study (142), and c-myc was
overexpressed in 8 of12 non-SCLC in anotherstudy(136).
myc Gene mRNA overexpression appears to occur more
frequentlyandisobservedearlierthangeneamplification.
Amplification ofthe myc genes is probably notinvolved in
the initiation ofhuman lungtumors butis related to latter
stages oftumor progression (136).
Esophageal Squamous Carcinomas. Coamplification
of int-2/hst-1 genes was observed in 28% (143) and 52%
(144)ofesophagealsquamous carcinomas andin30%(143)
and 100% (144) of lymph node metastases. The survival
rateofpatientswithamplifiedint-2/hst-1geneswassignif-
icantlylower and the frequency ofdistant organ metasta-
sis higher than in patients with unamplified int-21hst-1
genes (143). The proteinproducts ofint-2/hst-1mayactas
paracrine growth factors for angiogenesis and thus aid in
the metastatic process.
Proto-oncogene amplification is usually associated with
progression of neoplasia rather than with initiation of
carcinogenesis. Gene amplification is a very rare event in
normal cells (145,146) and the observed amplification in
tumor cells may reflect their genetic instability (147). In
several recent reports, however, HER2/neu was observed
to be amplified in early clinical stages; thus, amplification
ofthis gene may also be important in the early stages of
some mammary tumorigenesis (129,130,148). Whereas
gene amplification is almost always accompanied by pro-
tein overexpression, some tumors with a single copy of a
proto-oncogene may overexpress the protein. The role of
gene overexpression, in the absence ofgene amplification,
in the tumorigenic process is unclear. The overexpression
could result from mutations in other genes and thus be
regarded as a consequence of the development of the
tumor; alternatively, alterations in the regulatory regions
ofaproto-oncogene, e.g, HER2Z/neu inmammarytumors
or myc genes in lung tumors, could result in overexpres-
sion and thus itself be an important step in the tumori-
genesis.
These examples demonstrate that amplification of
proto-oncogenes and possibly gene overexpression in the
absence ofgene amplification are important events in the
development ofmanyhuman tumors. For aspecific tumor
type,amplificationofanyoneproto-oncogenemayoccurat
a low frequency, but the frequency oftumors in which at
least one proto-oncogene is amplified may be relatively
high.
Only a few reports have been published ofgene ampli-
ficationinrodenttumors: the c-myc genewas amplifiedin
8 of12 ratskintumorsinducedbyionizingradiation (149);
theHa-rasgenewasamplifiedaswellasmutatedinmouse
skin tumors induced by 7.12-dimethylbenz[a]anthracene
(DMBA) (150); amplification ofH-ras and HER2/neuwas
observed in oral cancers induced by DMBA in hamsters
(151).Thepaucityofobservationsofproto-oncogene ampli-
fication in rodent tumors may be a reflection of a lack of
systematic investigation for amplified proto-oncogenes in
malignant tumors.
Genomicrearrangements are commonlyencountered in
the karyotypes of cancer cells. The significance of these
rearrangementshasbeenelucidatedinseveralcaseswhen
the altered gene was identified as a proto-oncogene. For
example, c-mycisjoined tovariousimmunoglobulin genes
in more than 95% of Burkitt's lymphomas (152-154) and
murineplasmacytomas (155-157). C-myc gene rearrange-
ments analogous to those observed in sporadic Burkitt's
lymphomas were detected in 12 of 16 cases of AIDS-
associated non-Hodgkin's lymphoma (158). The transloca-
tions probably perturb transcriptional control of c-myc
and potentiate oncogenic growth of B cells (159). During
generation ofthePhiladelphiachromosome, foundinmore
than 90% of chronic myelogenous leukemias (160), the
tyrosine kinase domain of the c-abl proto-oncogene
located on 9q is moved to chromosome 22 andjoined to an
undefinedgeneticlocus,termed bcr, tocreateahybrid bcr-
abl protein with oncogenic potential (161). Chromosome
translocation mayindicatethepresence and chromosomal
location ofpreviouslyunidentified oncogenes; forexample,
bcl-2 is frequently activated (85-95%) by translocation in
follicular lymphomas (162,163).
Activated proto-oncogenes other than ras have also
been detected by DNA transfection methods in both
human and rodent tumors (3,12). The following examples
illustratethevarietyofnon-ras oncogenes detected inthe
NIHI3T3 focus assay and the nude mouse tumorigenicity
assay (164): a) Two proto-oncogenes that display tyrosine
kinaseactivity,retandtrk, havebeenfoundtobeactivated
by gene rearrangement in human papillary thyroid car-
cinomas (51). The authors originally referred to the rear-
ranged retproto-oncogene asPTC; theylater determined
thatPTCwas derivedfromrearrangementofanunknown
amino-terminal sequencewiththetyrosinekinasedomain
ofthe ret proto-oncogene. The trk proto-oncogene is also
activatedbyrearrangementofthetyrosinekinasedomain
ofthegenewith anunknownDNAsequence. Thetrkgene
was originally discovered in a colon carcinoma as an
oncogene derived by rearrangement of a gene with
tyrosine kinase activity (165). The ret oncogene was
detected in 9 of 36 papillary thyroid tumors, and the trk
oncogene was detected in 4 of 16 tumors. Distinct gene
rearrangementswereobservedineach ofthetumors that
contained one ofthese oncogenes. b) The HER2/neu and
hst-1proto-oncogenes, which areamplifiedin somehuman
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tumors, as discussed above, were originally detected by
DNAtransfection assays. Theneu oncogenewas detected
in neuroblastomas induced by N-ethyl-N-nitrosourea in
rats (166) and was activated by a point mutation in the
transmembrane region of the putative growth factor
receptor encoded byneu. The hst-1 oncogene was isolated
from a human gastric carcinoma (167). c) Atransforming
gene called Ica (168) was detected in two human hepato-
cellular carcinomas. d) An oncogene designated axi was
detected in a human myeloid leukemia (56); e) The c-raf
proto-oncogene can be activated artifactually during the
transfection process; however, in a human pulmonary
adenocarcinoma (45) and in two mouse hepatocellular
carcinomas (20),wedetectedanactivatedc-rafgeneintwo
independent transfection assays. This suggests that the
activated c-raf may be present in the original tumors.
B-raf oncogenes were also detected in two mouse
hepatocellular carcinomas (20).fl Several potentially new
types ofoncogenes that await characterization have been
detected in human lung tumors (45), mouse lung tumors
(80,90), rat nasal squamous carcinomas (169), mouse lym-
phomas (78,170), and rabbit SCC (91).
Recent studies involving the NIH/3T3 focus-forming
assay and the nude mouse tumorigenicity assays suggest
that some humantumortypes contain ahigh frequency of
activated proto-oncogenes. Oncogenes were detected in
62% ofpapillary thyroid tumors (51) and in 12 of14 (86%)
non-SCLC (45). The oncogenes detected include both ras
and non-ras genes. Thus, systematic examination of
human and rodent tumors by DNA transfection methods
may result in the detection of novel and/or previously
identified oncogenes at a relatively high frequency.
Summary
The activation and concerted expression of proto-
oncogenes are probably involved in the development of
mosthumanandrodenttumors. Itisverylikelythatnotall
of the oncogenes involved in the development ofprimary
tumors have been identified. The accumulation ofgenetic
damage in the forms of activated proto-oncogenes and
inactivated tumor-suppressor genes is the drivingforce in
the evolution of a normal cell to a malignant cell. ras
Oncogenes and mutated p53 genes have been observed in
the same human colon cancer cells (17), and it is possible
that some human mammary tumors have both a mutated
p53 gene and an amplified and overexpressed HER2/neu
gene(129,171). Earlierstudies showedthatcombinations of
oncogenes(i.e,mycplusras)couldcooperatetotransform
a cell, whereas each oncogene by itself was incapable of
elicitingtransformation ofanormalcell (2).Analternative
mechanism, which may operate in the development of
many primary tumors, is inactivation of a suppressor
gene(s), resulting in inappropriate expression of a proto-
oncogene(s); the inappropriately expressed proto-
oncogene(s) could then cooperatewith an activated proto-
oncogene(s) present in the cell to elicit transformation
analogous to that induced by myc plus ras. As additional
tumors are examined for both oncogene and suppressor
genes, more exampleswillbedetectedinwhich both types
ofaltered gene occur in the same tumor.
The etiology ofthe genetic alterations observed inmost
human tumors isunclear atpresent. The C toTmutations
at CpG sites in the p53 gene detected in human colon
tumors may very well occur spontaneously. In contrast,
the G to T mutation detected in non-SCLC at various
positions on the p53 gene and in the 12th codon of the
K-ras gene are probable consequences ofcigarette smok-
ing. The mutations in codon 278 ofthep53 gene observed
in some aflatoxin Bl-associated tumors could result from
chemical exposure. The ras mutations in skin tumors at
sun-exposedsitesareprobablyinducedbyultravioletradi-
ation. In most cases, however, the genetic alterations
observed in tumors are probably generated byboth spon-
taneous events and environmental insults. For sporadic
tumors, theinitiation step orearlygenetic alterations may
be caused directly or indirectly by exogenous agents, and
later events occur spontaneously.
This manuscript was presented at the Conference on Biomonitoring
and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona,
Hawaii, 26 October-1 November 1991.
REFERENCES
1. Bishop, J. M. Molecular themes in oncogenesis. Cell 64: 235-248
(1991).
2. Weinberg, R. A. Oncogenes, antioncogenes and the molecular basis
ofmultistep carcinogenesis. Cancer Res. 49: 3713-3721 (1985).
3. Anderson, M. W. and Reynolds, S. H. Activation of oncogenes by
chemical carcinogens. In: The Pathobiology ofNeoplasia (A. Sirica,
Ed.), Plenum Press, NewYork, 1989, pp. 291-304.
4. Bishop, J. M.Themoleculargenetics ofcancer. Science235: 303-311
(1987).
5. Hunter, T. Cooperation between oncogenes. Cell 64: 249-270 (1991).
6. Cantley, L. C., Auger, K. R., Carpenter, C, Duckworth, B. Graziani,
A., Kapeller, R, and Soltoff, S. Oncogenes and signal transduction.
Cell 64: 281-302 (1991).
7. Cross, M., and Dexter, T. M. Growth factors in development, trans-
formation, and tumorigenesis. Cell 64: 271-280 (1991).
8. Lewin, B. Oncogenic conversionbyregulatorychanges intranscrip-
tion factors. Cell 64: 303-312 (1991).
9. Bishop, J. M. Viral oncogenes. Cell 42: 23-38 (1985).
10. Varmus, H. An historical overview ofoncogenes. In: Oncogenes and
the Molecular Origin of Cancer (R. A. Weinberg, Ed.) CHS Press,
Cold Spring Harbor, NY, 1989, pp. 3-44.
11. Westin, E. H. Oncogenes. In: The Pathobiology of Neoplasia (A.
Sirica, Ed.), Plenum Press, NewYork, 1989, pp. 275-290.
12. Bishop, J. M. Oncogenes and clinical cancer. In: Oncogenes and the
Molecular Origin ofCancer (R. A.Weinberg, Ed.), CSH Press, Cold
Spring Harbor, NY, 1989, pp. 327-358.
13. Marshall, C. J. Tumor suppressor genes. Cell 64: 313-326 (1991).
14. Barrett, J. C., Oshimura, M, and Koi, M. Role of oncogenes and
tumorsuppressantgenesin amultistepmodel ofcarcinogenesis. In:
Symposium on Fundamental Cancer Research, Vol. 38 (F. Becker,
Ed.), University ofTexas Press, Austin, TX, 1987, pp. 45-56.
15. Hansen, M. F., and Cavenee, W. K. Ibmor suppressors: recessive
mutations that lead to cancer. Cell 53: 172-173 (1988).
16. Scrable, H.J., Sapienza, C, andCavenee,W. K. Geneticandepigene-
tic losses of heterozygosity in cancer predisposition and progres-
sion. Adv. Cancer Res. 54: 25-62 (1990).
17. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal
tumorigenesis. Cell 61: 759-767 (1990).
18. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D., and
Korsmeyer, S. J. Preventing cell suicide: a new role for oncogenes.
Nature 348: 334 (1990).
19. Barbacid, M. ras Genes. Annu. Rev. Biochem. 56: 780-813 (1987).PROTO-ONCOGENE ACTIVATION IN CARCINOGENESIS 21
20. Reynolds, S. H, Stowers, S. J, Maronpot, R. R, Aaronson, S. A, and
Anderson, M. W. Activated oncogenes in B6C3F1 mouse livertumors:
implications for risk assessment. Science 237: 1309-1317 (1987).
21. Sloan, S. R., Newcomb, E. W., and Pellicer, A. Neutron radiation can
activate K-ras via a point mutation in codon 146 and induces a
different spectrum of ras mutations than does gamma radiation.
Mol. Cell. Biol. 10: 405-408 (1990).
22. McCormick, F. ras Oncogenes. In: Oncogenes and the Molecular
Origin of Cancer (R. A. Weinberg, Ed.), CSH Press, Cold Spring
Harbor, NY, 1989, pp. 125-145.
23. Bourne, H. R., Sanders, D. A., and McCormick, F. The GTPase
superfamily: conservedstructureandmolecularmechanism. Nature
349: 117-127 (1991).
24. Valencia, A., Chardin, P., Wittinghofer, A, and Sander, C. The ras
protein family: evolutionary tree and role ofconserved amino acids.
Biochemistry 30: 4637-4648 (1991).
25. Downward,J.,Riehl,R.,Wu, L.,andWeinberg, R.A. Identification of
a nucleotide exchange-promoting activity for p2lra,,. Proc. Natl.
Acad. Sci. USA 87: 5998-6002 (1990).
26. Trahey, M., and McCormick, F. A cytoplasmic protein regulates
GTPase ofnormal N-rasp21,butdoes notaffectoncogenicmutants.
Science 238: 542-545 (1987).
27. Gibbs, J. B., Schaber, M. D.,Allard, W. J., Sigal, I. S., and Scolnick, E.
M. Purification ofras GTPase activating protein frombovine brain.
Proc. Natl. Acad. Sci. USA 85: 5026-5030 (1988).
28.Vogel, U. S., Dixon, R. A., Schaber, M. D., Diehl, R. E., Marshall, M.
S.,Scolnick, E.M.,Sigal, I.S.,andGibbs,J.B.CloningofbovineGAP
anditsinteractionwithoncogenicrasp21. Nature335: 90-93 (1988).
29. Pai, E. F., Krengel, U., Petsko, G. A., Goody, R. S., Kabsch, W., and
Wittinghofer, A. Refined crystal structure ofthe triphosphate con-
formation of H-ras p21 at 1.35 A resolution: implications for the
mechanism ofGTP hydrolysis. EMBO 9: 2351-2359 (1990).
30. Krengel, U, Schlichting, I,Scherer,A, Schumann, R., Frech, M,John,
J, Kabsch, W, Pai, E. F, and Wittinghofer, A. Three-dimensional
structures ofH-rasp21 mutants: molecularbasis fortheirinability to
function as signal switch molecules. Cell 62: 539-548 (1990).
31. Milburn, M. V., Tong, L., DeVos, A. M., Brunger, A., Yamaizumi, Z.,
Nishimura, S., andKim,S. Molecularswitch forsignaltransduction:
structural differencesbetween active andinactiveforms ofprotoon-
cogenic ras proteins. Science 247: 939-945 (1990).
32. Pai, E., Kabsch, W., Krengel, U., Holmes, K., John, J., and Wit-
tinghofer,A. Structure oftheguanine-nucleotide-binding domain of
the Ha-ras oncogeneproductp21 in thetriphosphate conformation.
Nature 341: 209-214 (1989).
33. Farr, C. J., Marshall, C. J., Easty, D. J., Wright, N. A., Powell, S. C.,
andParaskeva,C.Astudyofrasgenemutationsincolonicadenomas
from familial polyposis coli patients. Oncogene 3: 673-678 (1988).
34. Vogelstein, B, Fearon, E. R, Hamilton, S. R.,Kern, S. E.,Presinger,
A. C., Leppert, M., Nakamura, Y, White, R., Smits, A. M. M., and
Bos, J. L. Genetic alterations during colorectal-tumor development.
N. Engl. J. Med. 319: 525-532 (1988).
35. Perucho, M., Forrester, K., Almoguera, C., Kahn, S, Lama, C.,
Shibata, D., Arnheim, N., and Grizzle, W. E. Expression and muta-
tional activation ofthe c-Ki-ras gene in human carcinomas. Cancer
Cells 7: 137-141 (1989).
36. Burmer, G. C. and Loeb, L. A. Mutations in the Kras2 oncogene
during progressive stages of human colon carcinoma. Proc. Natl.
Acad. Sci. USA 86: 2403-2407 (1989).
37. Bos, J. L., Fearon, E. R, Hamilton, S. R., Verlaan-de Vries, M, van
Boom, J. H., van der Eb, A. J, and Vogelstein, B. Prevalence ofras
gene mutations in human colorectal cancers. Nature 327: 293-299
(1987).
38. Burmer, G. C., Rabinovitch, P S., and Loeb, L. A. Frequency and
spectrum ofc-Ki-ras mutations in human sporadic colon carcinoma,
carcinomas arising in ulcerative colitis, and pancreatic adenocar-
cinoma. Environ. Health Perspect. 93: 27-31 (1991).
39. Oudejans, J. J., Slebos, R. J. C., Zoetmulder, F, Mooi, W. J., and
Rodenhuis, S. Differential activation ofras genes bypoint mutation
in colon cancer with metastases to either lung or liver. Proc. Am.
Assoc. Cancer Res. 32: 293 (1991).
40. Mariyama,M.,Kishi,K.,Nakamura, K.,Obata,H.,andNishimura, S.
Frequency and types of point mutation at the 12th codon of the
c-Ki-ras gene found in pancreatic cancers from Japanese patients.
Jpn. J. Cancer Res. 80: 622-626 (1989).
41. Grunewald, K., Lyone, J., Frohlich, A., Feichtinger, H., Weger, R.A.,
Schwab, G, Janssen, J.W. G., and Bartram, C. R. High frequency of
Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int. J.
Cancer 43: 1037-1041 (1989).
42. Smit, V. T. H. B. M., Boot, A. J. M., Smits, A. M. M., Fleuren, G. J.,
Cornelisse, C. J., and Box, J. L. K-ras codon 12mutations occurvery
frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 16:
7773-7782 (1988).
43. Shibata, D., Almoguera, C., Forrester, K., Dunitz, J., Martin, S. E.,
Cosgrove, M.M.,Perucho,M., andArnheim, N. Detection ofc-K-ras
mutations infine needle aspirates from humanpancreatic adenocar-
cinomas. Cancer Res. 50: 1279-1283 (1990).
44. Rodenhuis, S., Siebos, R.J.C.,Boot,A.J.M.,Evers, S.G.,Mooi,W.J.,
Wagenaar, S. S., Bodegom, P. C., and Bos, J. L. Incidence and
possible clinical significance of K-ras oncogene activation in ade-
nocarcinoma ofthe human lung. Cancer Res. 48: 5738-5741 (1988).
45. Reynolds, S. H., Anna, C. K., Brown, K. C.,Wiest, J. S., Beattie, E.J.,
Pero, R. W., Iglehart, J. D., and Anderson, M.W. Activated protoon-
cogenes in human lung tumors from smokers. Proc. Natl. Acad. Sci.
USA 88: 1085-1089 (1991).
46. Suzuki, Y., Orita, M, Shiraishi, M., Hayashi, K., and Sekiya, T.
Detection of ras gene mutations in human lung cancers by single-
strand conformation polymorphism analysis of polymerase chain
reaction products. Oncogene 5: 1037-1043 (1990).
47. Slebos, R. J. C., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J.,
Meier, C. J. L. M., Wagenaar, S. S., Vanderschueren, R. G. J. R. A.,
van Zandwik, N., Mooi, W. J., Bos, J. L., and Rodenhuis, S. K-ras
oncogeneactivation asaprognosticmarkerinadenocarcinomaofthe
lung. N. Engl. J. Med. 323: 561-565 (1990).
48. Rodenhuis, S., van deWetering, M. L., Mooi, W. J., Evers, S. G., van
Zandwik, N., and Bos, J. L. Mutational activation of the K-ras
oncogene. N. Engl. J. Med. 317: 928-935 (1987).
49. Shi, Y., Zou, M., Schmidt, H., Juhasz, F., Stensky, V., Robb, D., and
Farid, N. R. Highrate ofras codon 61 mutation inthyroid tumors in
an iodide-deficient area. Cancer Res. 51: 2690-2693 (1991).
50. Lemoine,N.R.,Mayall, E.S.,Wyllie, F.S.,Williams,E.D.,Goyns,M,
Stringer, B., and Wynford-Thomas, D. High frequency of ras
oncogene activation in all stages of human thyroid tumorigenesis.
Oncogene 4: 159-164 (1989).
51. Bongarzone, I., Pierotti, M. A., Monzini, N., Mondellini, P., Manenti,
G., Donghi, R., Pilott, S., Grieco, M., Santoro, M., Fusco, A.,Vecchio,
G., and Della Porta, G. High frequency of activation of tyrosine
kinase oncogenes in human papillary thyroid carcinoma. Oncogene
4: 1457-1462 (1989).
52. Fusco, A., Grieco, M., Santoro, M., Berlingieri, M. T, Pilotti, S.,
Pierotti, M. A, Della Porta, G., and Vecchio, G. A new oncogene in
human thyroid papillary carcinomas and their lymph-nodal metas-
tases. Nature 328: 170-172 (1987).
53. Bos, J. L., Verlaan-de Vries, M., van der Eb, A. J, Janssen, J. W. G.,
Delwel, R., Lowenberg, B., and Colly, L. P. Mutations in N-ras
predominate in acute myeloid leukemia. Blood 69: 1237-1241 (1987).
54. Hirari, H., Kobayashi, Y., Mano, H, Hagiwara, K, Maru, Y., Omine,
M., Mizoguxhi, H., Nishida, J., and Takaku, F. A point mutation at
codon 13 of the N-ras oncogene in myelodysplastic syndrome.
Nature 327: 430-432 (1987).
55. Liu, E. Hjelle, B., Morgan, R., Hecht, F., andBishop, M. Mutationsof
thekirsten-rasproto-oncogeneinhumanpreleukaemia. Nature330:
186-188 (1987).
56. Liu,E,Hjelle,B.,andBishop M.¶fansforminggenesinchronicmyelo-
genous leukemia. Proc. Natl. Acad. Sci. USA 85: 1952-1956 (1988).
57. Ananthaswamy, H. N., Price, J. E., Goldberg, L. H., and Bales, E. S.
Detection and identification of activated oncogenes in human skin
cancers occurring onsun-exposedbodysites. Cancer Res. 48: 3341-
3346 (1988).
58. Pierceall, W. E. and Ananthaswamy, H. N. Mechanisms of ras
oncogene activation in humannonmelanoma skin cancers. Proc. Am.
Assoc. Cancer Res. 32: 140 (1991).
59. Corominas, M., Sloan, S. R., Leon, J., Kamino, H., Newcomb, E. W.,
andPellicer, A. rasActivation in human tumors andin animal model
systems. Environ. Health Perspect. 93: 19-25 (1991).
60. Van t'Veer, L. J., Burgering, B. M. T., Versteeg, R., Boot, A. J. M.,
Ruiter, D. J., Osanto, S., Schrier, P. I., and Bos, J. L. N-rasmutations
in human cutaneous melanoma from sun-exposed body sites. Mol.
Cell. Biol. 9: 3114-3116 (1989).22 ANDERSON ETAL.
61. Saranath, D., Chang, S. E., Bhoite, L. T, Panchal, R. G., Kerr, I. B.,
Mehta, A. R., Johnson, N. W, and Deo, M. G. High frequency
mutation in codons 12 and 61 ofH-ras oncogenein chewingtobacco-
related human oral carcinoma in India. Br. J. Cancer 63: 573-578
(1991).
62. Rumsby, G., Carter, R. L, andGusterson, B.A. Lowincidence ofras
oncogene activation in human squamous cell carcinomas. Br. J.
Cancer 61: 365-368 (1990).
63. Chang, S. E., Bhatia, P, Johnson, N. W., Morgan, P. R, McCormick,
F., Young, B, and Hiorns, L. ras Mutations in United Kingdom
examples oforalmalignancies areinfrequent. Int.J.Cancer48:409-
412 (1991).
64. Ochiya, T, Fujiyama, A, Fukushige, S., Hatada, I., and Matsubara,
K. Molecular cloning of an oncogene from a human hepatocellular
carcinoma. Proc. Natl. Acad. Sci. USA 83: 4993-4997 (1986).
65. Tsuda, H., Hirohashi, S, Shimosato, Y, Ino, Y, Yoshida, T., and
Terada, M. Low incidence ofpoint mutation ofc-Ki-ras and N-ras
oncogenes in human hepatocellular carcinoma. Jpn. J. Cancer Res.
80: 196-199 (1989).
66. Tada, M., Omata, M, and Ohto, M.Analysis ofrasgenemutations in
human hepatic malignant tumors bypolymerase chain reaction and
direct sequencing. Cancer Res. 50: 1121-1124 (1990).
67. Levi, S., Urbano-Ispizua, A., Gill, R., Thomas, D. M., Gilbertson, J,
Foster, C, and Marshall, C. J. Multiple K-ras codon 12 mutations in
cholangiocarcinomas demonstrated with a sensitive polymerase
chain reaction technique. Cancer Res. 51: 3497-3502 (1991).
68. Visvanathan, K., Pocock, R. D, andSummerhayes, I. C. Preferential
and novel activation of H-ras in human bladder carcinomas.
Oncogene Res. 3: 77-86 (1988).
69. Fujita, J., Srivastava, S. K., Kraus, M. H., Rhim, J. S.,Tfronick, S. R.,
andAaronson, S.A. Frequencyofmolecularalterations affectingras
protooncogenes in human urinary tract tumors. Proc. Natl. Acad.
Sci. USA 82: 3849-3853 (1985).
70. Enomoto, T., Inoue, M, Perantoni, A. O.,Terakawa, N.,Tanizawa, O.,
and Rice, J. M. K-ras activation in neoplasms ofthe human female
reproductive tract. Cancer Res. 50: 6139-6145 (1990).
71. Enomoto, T., Inoue, M., Perantoni, A. O., Tanizawa, O., Nomura, T.,
andRice,J. M. rasActivationinmalignantandpremalignantlesions
inhumanfemalereproductive tract. Am.Assoc. CancerRes. 32: 290
(1991).
72. Rochlitz, C. F, Scott, G. K., Dodson, J. M., Liu, E., Dollbaum, C,
Smith, H. S, and Benz, C. C. Incidence ofactivating ras oncogene
mutations associated with primary and metastatic human breast
cancer. Cancer Res. 49: 357-360 (1989).
73. Bailleul, B., Brown, K., Ramsden, M., Akhurst, R. J., Fee, F., and
Balmain, A. Chemical induction ofoncogene mutations and growth
factor activity in mouse skin carcinogenesis. Environ. Health Per-
spect. 81: 23-27 (1989).
74. Balmain, A. and Brown, K. Oncogene activation in chemical car-
cinogenesis. Adv. Cancer Res. 51: 147-182 (1988).
75. Guerrero, I, and Pellicer, A. Mutational activation of oncogenes in
animal model systems ofcarcinogenesis. Mutat. Res. 185: 293-308
(1987).
76. Brown, K., Buchmann, A., and Balmain, A. Carcinogen-induced
mutations in the mouse c-Ha-ras gene provide evidence ofmultiple
pathways fortumorprogression. Proc.Natl.Acad.Sci.USA87: 538-
542 (1990).
77. Sukumar, A. Involvement ofoncogenes in carcinogenesis. In: Cellu-
lar and Molecular Biology of Mammary Cancer (D. Medina, W.
Kidwell, G. Heppner, and E. Anderson, Eds.), Plenum Press, New
York, 1988, pp. 381-398.
78. Newcomb, E. W., Diamond, L. E, Sloan, S. R., Corominas, M,
Gurrerro, I., andPellicer,A. Radiation andchemicalactivation ofras
oncogenes in different mouse strains. Environ. HealthPerspect. 81:
33-37 (1989).
79. Sukumar, S. ras Oncogenes in chemical carcinogenesis. Microbiol.
Immunol. 148: 93-114 (1989).
80. Candrian, U.,You,M.,Goodrow,T.,Maronpot, R. R.,Reynolds, S. H.,
andAnderson, M.W.Activation ofprotooncogenesinspontaneously
occurring non-liver tumors from C57BL/6 times C3H Fl mice.
Cancer Res. 51: 1148-1153 (1991).
81.You, M, Candrian, U., Maronpot, R., Stoner, G, and Anderson, M.
Activation ofthe K-ras protooncogene in spontaneously occurring
and chemically-induced lung tumors of the strain A mouse. Proc.
Natl. Acad. Sci. USA 86: 3070-3074 (1989).
82. Belinsky, S, Devereux, T., Maronpot, R., Stoner, G., and Anderson,
M.Relationshipbetween theformationofpromutagenic adductsand
the activation ofthe K-ras protooncogene in lung tumors from A/J
mice treated with nitrosamines. Cancer Res. 49: 5305-5311 (1989).
83. Fox, T. R., Schumann, A. M., Watanabe, P. G., Yano, B. L., Maher, V.
M., andMcCormick, J. J. Mutational analysis ofthe H-ras oncogene
in spontaneous C57B1/6 times C3H/He mouse liver tumors and
tumors induced with genotoxic and nongenotoxic hepatocar-
cinogens. Cancer Res. 50: 4014-4019 (1990).
84. Sukumar, S., Notario,V., Martin-Zanca, D., and Barbacid, M. Induc-
tionofmammarycarcinomasinratsbynitroso-methyl-urea involves
malignant activation of H-ras-1 locus by single point mutations.
Nature 306: 658-661 (1983).
85. Zarbl, H., Sukumar, S., Arthur, A. V, Martin-Zanco, D., and Bar-
bacid, M. Direct mutagenesis of H-ras-1 oncogenes by nitroso-
methyl-urea during initiation of mammary carcinogenesis in rats.
Nature 315: 382-385 (1985).
86. Lemoine, N. R, Mayall, E. S., Williams, E. D., Thurston, V., and
Wynford-Thomas, D. Agent-specific ras oncogene activation in rat
thyroid tumours. Oncogene 3: 541-544 (1988).
87. Sukumar, S, Perantoni, A, Reed, C., Rice, J. M, and Wenk, M. L.
Activated K-ras and N-ras oncogenes in primary renal mesenchy-
mal tumors induced in F344 rats by methyl(methoxymethyl) nitro-
samine. Mol. Cell. Biol. 6: 2716-2720 (1986).
88. Wang,Y,You,M.,Reynolds, S.H.,Stoner,G.D,andAnderson,M.W.
Mutational activation of the cellular harvey ras oncogene in rat
esophageal papillomas induced by methylbenzylnitrosamine. Can-
cer Res. 50: 1591-1595 (1990).
89. Stowers, S. J., Gloves, P. L., Reynolds, S. H., Maronpot, R. R, Boone,
L. L., Aaronson, S. A., and Anderson, M. W. Activation ofthe K-ras
proto-oncogene in lung tumors from rats and mice chronically
exposed to tetranitromethane. Cancer Res. 47: 3212-3219 (1987).
90. Goodrow,T.,Reynolds,S.,Maronpot,R.,andAnderson,M.Activation
of K-ras by codon 13 mutations in C57BL/6 times C3H F1 mouse
tumorsinducedbyexposure to 1,3-butadiene. Cancer Res. 50:4818-
4823 (1990).
91. Corominas, M., Leon,J.,Kamino, H., Cruz-Alvarex, M., Novick, S. C.,
and Pellicer, A. Oncogene involvement in tumor regression: H-ras
activation in the rabbit keratoacanthoma model. Oncogene 6: 645-
651 (1991).
92. Fujii, H., Egami, H., Chaney, W, pour, P., and Pelling, J. Pancreatic
ductal adenocarcinomas induced in Syrian hamsters by N-nitro-
sobis(2-oxopropyl)amine contain a c-Ki-ras oncogene with a point-
mutated codon 12. Mol. Carcinog. 3: 296-301 (1990).
93. Reynolds, S. H.,Patterson, R.M.,Maronpot, R. R, andAnderson, M.
W. ras Gene activation in rat tumors induced bybenzidine cogeners
and derived dyes. Cancer Res. 50: 266-272 (1990).
94. Sinha, S, Webber, C., Marshall, C. J., Knowles, M. A., Proctor, A.,
Barrass, N. C, and Neal, G. E. Activation of ras oncogene in
aflatoxin-induced rat liver carcinogenesis. Proc. Natl. Acad. Sci.
USA 85: 3673-3677 (1988).
95. McMahon, G, Davis, E. F, Huber, L. J., Kim, Y., and Wogan, G. N.
Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin Bi-
induced rat liver tumors. Proc. Natl. Acad. Sci. USA 87: 1104-1108
(1990).
96. Wiseman, R., Stowers, S., Miller, E., Anderson, M., and Miller, J.
Activating mutations of c-Ha-ras protooncogenes in chemically
induced hepatomas of the male B6C3F1 mouse. Proc. Natl. Acad.
Sci. USA 83: 5285-5289 (1986).
97. Bonham,K.,Embry,T,Gibson, D.,Jaffe, D. R.,Roberts, R.A.,Cress,
A. E., and Bowden, G. T.Activation ofthecellularharveyrasgenein
mouse skin tumors initiated with urethane. Mol. Carcinog. 2: 34-39
(1989).
98. Miller, J. and Miller, E. The metabolic activation and nucleic acid
adducts of naturally-occurring carcinogens: recent results with
ethyl carbamate and the spice flavors safrole and estragole. Br. J.
Cancer 48: 1-15 (1983).
99. Leithauser, M.T., Liem,A,Stewart,B.C.,Miller,E.C.,andMiller,J.
A. l,N6-Ethenoadenosine formation, mutagenicity, and murine
tumor induction as indicators of the generation of an electrophilic
epoxide metabolite of the closely related carcinogens ethyl carba-
mate (urethane) and vinyl carbamate. Carcinogenesis 11: 463-473
(1990).PROTO-ONCOGENE ACTIVATION IN CARCINOGENESIS 23
100. Park, K. K*,Surh,Y.J.,Stewart, B.C, andMiller, J.A.Synthesis and
properties of vinyl carbamate epoxide, a possible ultimate elec-
trophilic and carcinogenic metabolite ofvinyl carbamate and ethyl
carbamate.Biochem.Biophys.Res.Commun.169:1094-1098(1990).
101. Tennant, R.W, Margolin, B. H, Shelby, M. D., Zeiger, E, Haseman, J..
K., Spalding, J.,Caspary,W, Resnick, M, Stasiewicz, S. Anderson, B.
andMinor, R.Predictionofchemicalcarcinogenicityinrodentsfromin
vitro genetic txicity assays. Science 236: 933-941 (1987).
102. Suzuki, T., Sobue, T., Fujimoto, I, Doi, 0., and Tateishi, R. Associa-
tion ofadenocarcinoma ofthe lungwith cigarettesmokingbygrade
ofdifferentiation and subtype. Cancer Res. 50: 444-447 (1990).
103. Phillips, D. H., Hewer,A., Martin, C. N., Garner, R. C., and King, M.
M. Correlation of DNA adduct levels in human lung with cigarette
smoking. Nature 336: 790-792 (1988).
104. Hollstein, M., Sidransky, D, Vogelstein, B., and Harris, C. C. p53
Mutations in human cancers. Science 253: 49-53 (1991).
105. Jones, P. A, Buckley, J. D, Henderson, B. E., Ross, R. K, and Pike,
M. C. From gene tocarcinogen: arapidlyevolvingfield inmolecular
epidemiology. Cancer Res. 51: 3617-3620 (1991).
106. Barbacid, M. ras Oncogenes: their role in neoplasia. Eur. J. Clin.
Invest. 20: 225-235 (1990).
107. Forrester, K., Almoguera, C., Han, K, Grizzle, W. E., and Perucho,
M. Detection of high incidence of K-ras oncogenes during human
colon tumorigenesis. Nature 327: 298-303 (1987).
108. Bar-Sagi, D., and Feramisco, J. R. Microinjection of the ras
oncogene protein into PC12 cells induces morphological differentia-
tion. Cell 42: 841-848 (1985).
109. Guerrero, I., Wong, H, Pellicer, A., and Burstein, D. E. Activated
N-ras gene induces neuronal differentiation of PC12 rat phe-
ochromocytoma cells. J. Cell. Physiol. 129: 71-76 (1986).
110. Nakagawa,T.,Mabry,M-deBustros,A.,Ihle,J.H.,Nelkin,B.D.,and
Baylin, S. B. Introduction ofv-Ha-ras oncogeneinduces differentia-
tion of cultured humanz medullary thyroid carcinoma cells. Proc.
Natl. Acad. Sci. USA 84: 5923-5927 (17U-
111. Seremetis, S., Inghirami, G.,Fgero,D., Newcomb, E., Knowles, D.,
Dotto, G.-P., and Dalla-Favera, R.Transformation andplasmacytoid
differentiation of EBV-infected human B lymphoblasts by ras
oncogenes. Science 243: 660-663 (1989).
112. Benito, M,Porras,A., Nebreda,A. R.,andSantos, E. Differentiation
of3T3-L1 fibroblasts to adipocytes induced by transfection of ras
oncogenes. Science 253: 565-568 (1991).
113. Landis, C.A, Master, S. B, Spada,A, Pace,A. M., Borne, H. R., and
Vallar, L.GTPaseinhibitingmutationsactivatetheachainofG8,and
stimulate adenylylcyclasein humanpituitary tumours. Nature 340:
692-698 (1989).
114. McCormick, F. Gasp: notjust another oncogene. Nature 340: 678-
679 (1989).
115. Lyons, J., Landis, C. A., Harsh, G., Vallar, L., Grunewald, K.,
Feichtinger, H, Duh, Q.-Y., Clark, 0. H., Kawasaki, E., Bourne, H.
R., andMcCormick, F.TwoGproteinoncogenes inhumanendocrine
tumors. Science 249: 655-659 (1990).
116. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., and
Bishop, J. M. Amplification of N-myc in untreated human neu-
roblastomas correlates with advanced disease stage. Science 224:
1121-1124 (1984).
117. Kohl, N.E., Legouy, E., DePinho, R.A, Nisen, P. D, Smith, R. K, Gee,
C.E,andAlt,F.W.HumanN-myciscloselyrelatedinorganizationand
nucleotide sequence to c-myc. Nature 319: 73-77 (1986).
118. Schwab, M, Ellison, J., Busch, M., Rosenau, W., Varmus, H. E., and
Bishop, J. M. Enhanced expression of the human gene N-myc
consequent to amplification of DNA may contribute to malignant
progression ofneuroblastoma. Proc. Natl. Acad. Sci. USA81: 4940-
4945 (1984).
119. Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E.,
Wong, K. Y., and Hammond, D. Association ofmultiple copies ofthe
N-myc oncogene with rapid progression of neuroblastomas. N.
Engl. J. Med. 313: 1111-1116 (1985).
120. Brodeur, G. M., Hayes, F. A., Green, A. A., Casper, J. T., Wasson, J.,
Wallach, S., and Seeger, R. C. Consistent N-myc copy number in
simultaneous or consecutive neuro-blastoma samples from sixty
individual patients. Cancer Res. 47: 4248-4254 (1987).
121. Grady-Leopardi, E. F., Schwab, M., Ablin, A. R., and Rosenau, W.
Detection of N-myc oncogene expression in human neuroblastoma
by in situ hybridization and blot analysis: relationship to clinical
outcome. Cancer Res. 46: 3196-3199 (1986).
122. Slamon, D. J. Proto-oncogenes andhuman cancers. N. Engl. J. Med.
317: 955-957 (1987).
123. Paterson, M.C.,Dietrich, K.D.,Danyluk,J.,Paterson,A.H.G.,Lees,
A. W., Jamil, N., Hanson, J., Jenkins, H., Krause, B. E., McBlain, W.
A., Slamon, D. J., and Fourney, R. M. Correlation between c-erb B-2
amplification and risk ofrecurrent disease in node-negative breast
cancer. Cancer Res. 51: 556-567 (1991).
124. Meyers, S. L., O'Brien, M. T, Smith, T, and Dudley, J. P. Analysis of
the int-1, int-2, c-myc, and neu oncogenes in human breast car-
cinomas. Cancer Res. 50: 5911-5918 (1990).
125. Adnane, J., Gaudray, P., Simon, M.-P, Simony-Lafontaine, J., Jean-
teur, R, and Theillet, C. Proto-oncogene amplification and human
breast tumor phenotype. Oncogene 4: 1389-1395 (1989).
126. Escot, C., Theillet, C, Lidereau, R, Spyratos, F., Champeme, M.-H.,
Gest, J., and Callahan, R. Genetic alteration of the c-myc protoon-
cogene (MYC) in human primary breast carcinomas. Proc. Natl.
Acad. Sci. USA 83: 4834-4838 (1986).
127. Borg, A, Sigurdsson, H., Clark, G. M., Ferno, M., Fuqua, S. A. W,
Olsson, H., Killander, D., and McGurie, W. L. Association of
int-2/hstl coamplification in primary breast cancer with hormone-
dependentphenotype and poorprognosis. Br. J. Cancer 63: 136-142
(1991).
128. Clark, G. M. and McGuire, W. L. Follow-up study of her-2/neu
amplification in primary breast cancer. Cancer Res. 51: 944-948
(1991).
129. Iglehart, J. D., Kraus, M. H., Langton, B. C., Huper, G., Kerns, B. J.,
and Marks, J. R. Increased erbB-2 gene copies and expression in
multiple stages ofbreast cancer. Cancer Res. 50: 6701-6707 (1990).
130. McCann, A. H., Dervan, P. A., O'Regan, M., Codd, M. B., Gullick, W.
J., Tobin, B. M. J., and Carney, D. N. Prognostic significance of
c-erbB-2 and estrogen receptor status in human breast cancer.
Cancer Res. 51: 3296-3303 (1991).
131. Ranzani, G. N., Pellegata, N. S., Previdere, C., Saragoni, A., Vio, A.,
Maltoni, M., and Amadori, D. Heterogeneous protooncogene ampli-
fication correlateswith tumorprogression andpresence ofmetasta-
ses in gastric cancer patients. Cancer Res. 50: 7811-7814 (1990).
132. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G.,
Keith, D. E, Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and
Press, M. F. Studies of the her-2/neu proto-oncogene in human
breast and ovarian cancer. Science 244: 707-712 (1989).
133.Yokota, J., Yamamoto, T., Toyoshima, K., Terada, M., Sugimura, T.,
Battifora, H., and Cline, M. J. Amplification ofc-erbB-2 oncogene in
human gastric carcinomas in vivo. Lancet i: 765-767 (1986).
134.Yokota, J, Yamamoto, T., Miyajima, N., Toyoshima, K, Nomura, N.,
Sakamoto, H, Yoshida, T., Terada, M., and Sugimura, T. Genetic
alterations of the c-erbB-2 oncogene occur frequently in tubular
adenocarcinoma of the stomach and are often accompanied by
amplification ofthe v-erbAhomologue. Oncogene 2: 283-287 (1988).
135. Kameda, T., Yasui, W., Yoshida, K., Tsujino, T., Nakayama, H., Ito,
M., Ito, H., and Tahara, E. Expression of erbB2 in human gastric
carcinomas: relationship between p185 erbB2 expression and the
gene amplification. Cancer Res. 50: 8002-8009 (1990).
136. Gazzeri,S.,Brambilla,E.,Jacrot,M.,Chauvin,C.,Benabid,A. L.,and
Brambilla, C. Activation of myc gene family in human lung car-
cinomas and during heterotransplantation into nude mice. Cancer
Res. 51: 2566-2571 (1991).
137. Johnson, B. E., Makuch, R.W.,Simmons, A. D.,Gazdar,A. F.,Burch,
D., and Cashell, A. W. myc Family DNA amplification in small cell
lung cancer patient's tumors and corresponding cell lines. Cancer
Res. 48: 5163-5166 (1988).
138. Takahashi, T., Obata, Y, Sekido, Y., Hida, T., Watanabe, R. U. H.,
Ariyoshi, Y, Sugiura, T., and Takahashi, T. Expression and ampli-
fication ofmyc genefamilyin small cell lung cancer and its relation
to biological characteristics. Cancer Res. 49: 2683-2688 (1989).
139. Gemma, A., Nakajima, T., Shiraishi, M., Noguchi, M., Gotoh, M.,
Sekiya,T.,Niitani,H.,andShimosato,Y.mycFamilygeneabnormal-
ity in lung cancers and its relation to xenotransplantability. Cancer
Res. 48: 6025-6028 (1988).
140. Shiraishi,T.,Noguchi,M.,Shimosato,Y., andSekiya,T.Amplification
ofprotooncogenes insurgical specimens ofhuman lung carcinomas.
Cancer Res. 49: 6474-6479 (1989).
141. Cline, M. J., and Battifora, H. Abnormalities ofprotooncogenes in
non-small cell lung cancer. Cancer 60: 2669-2674 (1987).24 ANDERSON ET AL.
142. Funa, K., Steinholtz, L., Nou, E., and Bergh, J. Increased expression
of N-myc in human small cell lung cancer biopsies predicts lack of
response to chemotherapy and poor prognosis. Am. J. Clin. Pathol.
88: 216-220 (1987).
143. Kitagawa, Y., Ueda, M., Ando, N., Shinozawa, Y., Shimizu, N., and
Abe, 0. Significance of int-2/hst-1 coamplification as a prognostic
factorinpatientswithesophageal squamous carcinoma. CancerRes.
51: 1504-1508 (1991).
144. Tsuda, T, Tahara, E, Kajiyama, G, Sakamoto, H, Terada, M, and
Sugimura,T. Highincidenceofcoamplification ofhst-1 andint-2 genes
in human esophageal carcinomas. Cancer Res. 49: 5505-5508 (1989).
145. Stark, G. R., Debatisse, M., Giulotto, E., and Wahl, G. M. Recent
progress in understanding mechanisms ofmammalian DNA ampli-
fication. Cell 57: 901-908 (1989).
146. Wright, J. A., Smith, H. S., Watt, F. M, Hancock, M. C Hudson, D.
L.,and Stark, G. R. DNAamplification israreinnormt humancells.
Proc. Natl. Acad. Sci. USA 87: 1791-1795 (1990).
147. Tlsty, T. D., Margolin, B. H., and Lum, K. Differences in the rates of
gene amplification in nontumorigenic and tumorigenic cell lines as
measured by Luria-Delbruck fluctuation analysis. Proc. Natl. Acad.
Sci. USA 86: 9441-9445 (1989).
148. Lacroix, H., Iglehart, J. D., Skinner, M. A, and Kraus, M. H.
Overexpression oferbB-2 or EGF receptorproteins present in early
stage mammary carcinoma is detected simultaneously in matched
primary tumors and regional metastases. Oncogene 4: 145-151
(1989).
149. Sawey, M. J, Hood, A. T., Burns, F. J., and Garte, S. J. Activation of
myc and ras oncogenes in primary rat tumors induced by ionizing
radiation. Mol. Cell. Biol. 7: 932-935 (1987).
150. Quintanilla, M., Brown, K., Ramsden, M., and Balmain, A.
Carcinogen-specific mutation and amplification of Ha-ras during
mouse skin carcinogenesis. Nature 322: 78-80 (1986).
151. Wong, D. T. W., and Biswas, D. K. Expression of c-erb B oncogene
during dimethylbenzanthracene-induced tumorigenesis in hamster
cheek pouch. Oncogene 2: 67-72 (1988).
152. Croce, C. M., Thierfelder, W., Erikson, J., Nishikura, K., Finan, J.,
Lenoir, G. M, and Nowell, P. C. Transcriptional activation of an
unrearranged and untranslocated c-myc oncogene bytranslocation
ofa cX locus in Burkitt lymphoma cells. Proc. Natl. Acad. Sci. USA
80: 6922-6926 (1983).
153. Dalla-Favera, R., Bregni, M., Erikson, J., Patterson, D., Gallo, R. C.,
and Croce, C. M. Human c-myc oncogene is located on the region of
chromosome 8 that is translocated in Burkitt lymphoma cells. Proc.
Natl. Acad. Sci. USA 79: 7824-7827 (1982).
154. Erikson, J., Nishikura, K, Ar-Rushdi, A., Finan, J, Emanuel, B.,
Lenoir, G., Nowell, P. C., and Croce, C. M. Translocation of an
immunoglobulin k locus to a region 3' of a unnrearranged c-myc
oncogene enhances c-myc transcription. Proc. Natl. Acad. Sci. USA
80: 7581-7585 (1983).
155. Cory, S., Gerondakis, S, andAdams, J. M. Interchromosomal recom-
bination of the cellular oncogene c-myc with the immunoglobulin
heavy chain locus in murine plasmacytomas is a reciprocal ex-
change. EMBO J. 2: 697-703 (1983).
156. Shen-Ong,G. L.C.,Keath, E.J.,Piccoli, S.P.,andCole,M. Novelmyc
oncogene RNA from abortive immunoglobulin-gene recombination
in mouse plasmacytomas. Cell 31: 443-452 (1982).
157. Stanton, L. W., Watt, R., and Marcu, K. B. Translocation, breakage,
and truncated transcripts of c-myc oncogene in murine plas-
macytomas. Nature 303: 401-406 (1983).
158. Subar, M., Neri,A., Inghirami, G., Knowles, D. M., andDalla-Favera,
R. Frequent c-myc oncogene activation and infrequent presence of
Epstein-Barr virus genome in AIDS-associated lymphoma. Blood
72: 667-671 (1988).
159. Leder, P.,Battery,J., Lenoir, G., Moulding, C., Murphy,W.,Potter, H.,
Stewart, T., and Taub, R. Translocations among antibody genes in
human cancer. Science 22: 765-771 (1984).
160. Groffen, J., Stephenson, J. R., Heisterkamp, N., deKlein, A., Bar-
tram, C. R., andGrosveld, G.Philadelphia chromosomalbreakpoints
areclusteredwithin alimitedregion, bcr, onchromosome22. Cell36:
93-99 (1984).
161. Konopka,J. B.,Watanabe, S. M., andWitte, 0. N.An alteration ofthe
human c-abl protein in K562 leukemia cells unmasks associated
tyrosine kinase activity. Cell 37: 1035-1042 (1984).
162. Tsujimoto, Y., and Croce, C. M. Analysis of the structure, tran-
scripts, andproteinproducts ofthebcl-2,thegeneinvolvedinhuman
follicular lymphoma. Proc. Natl. Acad. Sci. USA 83: 5214-5218
(1986).
163. Tsujimoto, Y., Ikegaki, Y. N., and Croce, C. M. Characterization of
the protein product of bcl-2, the gene involved in human follicular
lymphoma. Oncogene 2: 3-9 (1988).
164. Fasano, O., Birnbaum, D., Edlund, L., Fogh, J., and Wigler, M. New
humantransforminggenesdetected byatumorigenicity assay. Mol.
Cell. Biol. 4: 1695-1705 (1984).
165. Martin-Zanca, D., Hughes, S. H., and Barbacid, M. A human
oncogene formed by the fusion oftruncated tropomyosin and pro-
tein kinase sequences. Nature 319: 743-748 (1986).
166. Schechter,A. L.,Stern,D. F.,Vaidyanathan, L., Decker, S.J., Drebin,
J. A., Greene, M. I., and Weinberg, R. A. The neu oncogene: an erb-
B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:
513-516 (1984).
167. Sakamoto, H., Mori, M., Taira, M., Yoshida, T., Matsukawa, S.,
Shimizu, K., Sekiguchi, M.,Terada, M., andSugimura, T. Transform-
ing gene from human stomach cancers and a noncancerous portion
of stomach mucosa. Proc. Natl. Acad. Sci. USA 83: 3997-4001
(1986).
168. Ochiya, T., Fujiyama, A., Fukushige, S., Hatada, I., and Matsubara,
K. Molecular cloning of an oncogene from a human hepatocellular
carcinoma. Proc. Natl. Acad. Sci. USA 83: 4993-4997 (1986).
169. Hochwalt,A. E.,Wirgin, I., Felber, M., Currie, D. D, and Garte, S. J.
Detection of novel non-ras oncogenes in rat nasal squamous cell
carcinomas. Mol. Carcinog. 1: 4-6 (1988).
170. Newcomb, E. W., Steinberg, J.J., andPellicer, A. ras Oncogenes and
phenotypic staging in N-methylnitrosourea-and y-irradiation-
induced thymic lymphomas in C57BL/6J mice. Cancer Res. 48:
5514-5521 (1988).
171. Davidoff, A. M., Kerns, B. M., Iglehart, J. D., and Marks, J. R.
Maintenance ofp53 alterations throughout breast cancer progres-
sion. Cancer Res. 51: 2605-2610 (1991).